In this article, we examine ongoing challenges shaping target-based drug discovery and highlight how new technologies and ...

In the pharmaceutical discovery process, understanding a drug’s residence time—the duration a molecule remains bound to its ...

Multi-year partnership with France's Servier will use Insilico's AI platform to explore novel cancer drugs Newly Hong ...

This article is based on a poster originally authored by Daniel A. Barr, Mario Öeren, Peter A. Hunt, Jonathan D. Tyzack, Tomáš Chrien, Tamsin E. Mansley and Matthew D. Segall, which was presented at ...

In the realm of modern medicine, RNA-based therapies have emerged as a promising avenue, with significant advancements in metabolic diseases, oncology, and preventive vaccines. A recent article ...

Explore how AI-driven multiomics is reshaping drug discovery and personalized medicine development through innovative data ...

Matthias Trost (left) is a Professor at Newcastle University (UK) with a lab comprising three focuses: method development for proteomics, the application of mass spectrometry in drug discovery and the ...

Every year, the media informs us that we’re on the cusp of the golden age of something. While the expected trend often comes to fruition, it’s rarely as smooth a process as advertised. Drug discovery ...

Krystyn Van Vliet, PhD, of Cornell University, discusses the scalability of 3D platforms in multiple sclerosis (MS) drug discovery and compares their costs with those of other drug discovery methods.

In a quest to develop new antiviral drugs for COVID-19 and other diseases, a collaboration led by scientists at The Wertheim UF Scripps Institute has identified a potential new drug against the virus ...